Market Access/ News/ News

NICE changes tack on NHS use of BMS’ myelofibrosis drug Inrebic

, , , , , , 0 Comment

After turning down routine NHS funding of Bristol-Myers Squibb’s Inrebic for bone marrow disorder myelofibrosis earlier this year,